<DOC>
	<DOC>NCT02200081</DOC>
	<brief_summary>Evaluation of efficacy and safety of MGN1703 administered twice weekly subcutaneously (SC) as maintenance treatment in patients with extensive disease small cell lung cancer (SCLC) who achieved at least a partial response (PR) following platinum-based first-line therapy.</brief_summary>
	<brief_title>Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<criteria>1. Male and female patients with extensive disease SCLC ≥ 18 years of age receiving first line treatment; 2. Histology of SCLC or mixed histology of SCLC if SCLC histology is at least 80%; 3. Completion of 4 cycles of firstline therapy with a platinumbased regimen and no other prior chemotherapy; 4. Documented evidence of tumor response as assessed by investigators after the first 2 cycles of platinumbased chemotherapy followed by a confirmed PR or CR at the end of fourth cycle by CT or MRI scan; 5. Brain metastases are allowed only after cranial irradiation, if not requiring continuous treatment with steroids or anticonvulsants; 6. ECOG performance status 0 or 1; 7. Adequate organ function with total bilirubin, lactate dehydrogenase [LDH], alkaline phosphatase [AP], gamma glutamyltransferase [GGT], albumin, creatinine, urea, electrolytes, and coagulation parameters ≤ 1.5 × upper limit of normal (ULN), and with aspartate aminotransferase [AST] and ALT ≤ 2.5 × ULN in the absence of liver metastases or ≤ 5.0 × ULN in the presence of liver metastases; 8. Adequate hematological parameters: absolute neutrophil count ≥ 1.5 × 109/L; platelet count ≥ 100 × 109/L; leukocyte count ≥ 3.0 × 109/L; lymphocytes ≥ 1.0 × 109/L; hemoglobin ≥ 9.0 g/dL or 5.59 mmol/L; 9. Patients with reproductive potential agree to use effective contraceptive measures throughout the study; 10. Negative pregnancy test in women of childbearing potential; 11. Signed informed consent form (ICF).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Extensive disease</keyword>
	<keyword>After first line therapy</keyword>
	<keyword>Immuno therapy</keyword>
</DOC>